Arjun L Uppar

Mr. Arjun L Uppar

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
SPShabi Parvez
Shabi Parvez
APAnushree Pathrathota
Anushree Pathrathota
AUArjun L Uppar
Arjun L Uppar
GYGanesh Yadagiri
Ganesh Yadagiri
SMShyam Lal Mudavath
Shyam Lal Mudavath
Influenza is a serious and global health issue, and it is a major cause of morbidity, fatality, and economic loss every year. Seasonal vaccines exist but are not very effective due to strain mismatches, delays in production, and antigenic drift. This comprehensive overview discusses the current situation of influenza vaccination, including the numerous types of vaccines—inactivated, live attenuated, and recombinant vaccines—and their effectiveness, efficacy, and associated challenges. It highlights the effects of the COVID-19 pandemic on the trends of influenza vaccination and the level to which innovation should be practiced. In the future universal influenza vaccines will be developed that target conserved viral antigens to provide long-term protection to people. In the meantime, novel vaccine delivery platforms, such as mRNA technology, virus-like particle (VLP), and nanoparticle-based systems, and less cumbersome and invasive administration routes, as well as immune responses are also under development to increase access and production capacity. Collectively, these innovations have the potential to not only reduce the global influenza epidemic but also to change the way influenza is prevented and prepare the world for a pandemic.

15 April 2026 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
AUArjun L Uppar
Arjun L Uppar
CPChandrashekar C. Patil
Chandrashekar C. Patil
SNShashank Namannavar
Shashank Namannavar
PDPankaj Ajit Deshmane
Pankaj Ajit Deshmane
The goal of the current study was to create and assess a cubosomal hydrogel loaded with caffeine for long-term topical administration. Due to its hydrophilic nature, caffeine, which is widely utilized for its antioxidant, lipolytic, and skin-stimulating qualities, has limited skin permeability in traditional formulations. Glyceryl monooleate (GMO) and Poloxamer 407 were used in the top-down procedure to create cubosomes in order to get over this restriction. Particle size, polydispersity index (PDI), zeta potential, morphology, entrapment efficiency, and compatibility tests were assessed for the produced formulations. With a particle size of 280.4 nm, a PDI of 0.3461, and a zeta potential of −23.64 mV, F3 demonstrated the best qualities among the produced formulations, indicating satisfactory stability. F3's entrapment efficiency was determined to be 88.915 ± 0.148%. After being integrated into a Carbopol 934 hydrogel, the improved cubosomal dispersion was assessed for physicochemical characteristics. The gel had an appropriate pH of 6.72 ± 0.48, a viscosity of 13285 ± 6.12 cps, good spreadability, a consistent drug content of 95.382 ± 0.864%, and no grittiness. Caffeine was shown to be released continuously for up to 24 hours (82.756%), in-vitro drug release tests using Franz diffusion cells, which followed Higuchi diffusion kinetics. Formulation parameters did not significantly change throughout 90-day stability testing. Overall, the findings point to cubosomal hydrogel filled with caffeine as a potential method for improved and long-lasting topical medication administration. Keywords: Caffeine; Cubosomes; Topical drug delivery; Carbopol hydrogel; Sustained release

15 April 2026 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
SNShashank Namannavar
Shashank Namannavar
CPChandrashekar C. Patil
Chandrashekar C. Patil
AUArjun L Uppar
Arjun L Uppar
SJSneha Jakaraddi
Sneha Jakaraddi
The effective encapsulation of hydrophilic and lipophilic medications is made possible by cubosomes, which are nanostructured lipid carriers with a bicontinuous cubic liquid crystalline structure. Nicotine Polacrilex-loaded cubosomal Nanogel was designed and characterized in this study to improve topical drug delivery. Glyceryl monooleate (GMO) was used as the lipid and Poloxamer 407 as the stabilizer in the top-down method of creating cubosomes. The optimized cubosomal dispersion (NP3) demonstrated acceptable stability and nanoscale size with a zeta potential of -15.57 mV, a particle size of 134.6 nm, Drug content of nanogel of 91.22+ 0.34% and a high entrapment efficiency of 90.71 + 0.42%. A cubosomal Nanogel formulation was created by combining the optimized dispersion with Carbopol 934 gel base. The produced gel had a smooth appearance, good homogeneity, a suitable viscosity (12358 + 6.12 cps), an acceptable pH (6.52 + 0.59), and a satisfactory spreadability (17.963 + 0.842 g·cm/sec). Diffusion-controlled drug release was indicated by Franz diffusion cell in vitro drug release studies, which showed sustained release behavior for up to 6 hours after Higuchi diffusion kinetics (R2 = 0.9799). Ultimately, the Nicotine Polacrilex-loaded cubosomal Nanogel showed promise as a topical drug delivery system with sustained release. Keywords: Nicotine Polacrilex, Cubosomes, Topical drug delivery, Carbopol Nanogel, Sustained release

15 April 2026 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
SJSneha Jakaraddi
Sneha Jakaraddi
CPChandrashekar C. Patil
Chandrashekar C. Patil
AUArjun L Uppar
Arjun L Uppar
SNShashank Namannavar
Shashank Namannavar
The aim of present work is to development and characterization of caffeine-loaded niosomal hydrogel for topical delivery. The stratum corneum significantly limits the effectiveness of conventional topical drug delivery systems. Vesicular carriers such as niosomes have emerged as a promising strategy to enhance dermal penetration and provide sustained drug release. The present study focused on development and characterization of a caffeine-loaded niosomal hydrogel intended for its antioxidant, lipolytic, and skin stimulating properties. Niosomes were prepared using a ether injection technique with different ratios of Tween 80 and cholesterol and were subsequently incorporated into a Carbopol 934 hydrogel base. Comprehensive characterization was performed, including particle size analysis, zeta potential measurement, FTIR compatibility studies, rheological assessment, spreadability, homogeneity, drug content, entrapment efficiency, and in-vitro drug release. Among the prepared formulations, batch CG4 demonstrated the highest entrapment efficiency (86.925 ± 0.165%) and was selected as the optimized system. The optimized niosomes exhibited a mean particle size of 448.1 nm and a zeta potential of -4.877 mV, indicating satisfactory vesicle stability. The corresponding niosomal hydrogel (NG1) showed desirable physicochemical properties, including pH 6.2 ± 0.58, viscosity 14235 ± 7.12 cps, excellent spreadability (17.963 ± 0.842 g·cm/sec), uniform consistency, and absence of grittiness, drug content (92.32 ±0.42). In-vitro release studies revealed a sustained release pattern of caffeine (81.9% over 12 hours), predominantly following first-order and Higuchi release kinetics. Overall, the development and characterization of caffeine-loaded niosomal hydrogel demonstrates strong potential as an effective topical delivery system for enhanced and sustained topical drug delivery. Keywords : Caffeine, Niosomes, Hydrogel, Viscosity, pH, Spreadability etc